The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34993136/
Advanced genome-wide association studies (GWAS) identified several transforming mutations in susceptible loci which are recognized as valuable prognostic markers in chronic lymphocytic leukemia (CLL) and B cell lymphoma (BCL). Alongside,...
Conclusion/Relevance: "Altogether, we propose a model of malignant transformation in which the augmented BCR signaling creates a conducive platform for the appearance of transforming mutations."
Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib
Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disease that accounts for 1.1% of all cancer diagnosis in the US. Historically, the therapeutic armamentarium against CLL consisted of chemotherapy agents,...
Relevance: "We delineate the safety profile of the drug, describe side effects of interest and discuss the clinical management of patients receiving acalabrutinib. Due to its efficacy and the favorable safety profile, acalabrutinib has emerged as a viable therapy option in the current landscape of multiple approved treatments for CLL."
Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway
Source : https://peerj.com/articles/12571/
Ibrutinib, a bruton tyrosine kinase (BTK) inhibitor which suppresses B-cell receptor signaling, has remarkably improved the outcome of patients with mantle cell lymphoma (MCL). However, approximately 33% of MCL patients...
Conclusions: “Taken together, the current results demonstrate that LINK-A inhibition overcomes Ibrutinib resistance in MCL cells by regulating AKT/Bcl2 pathway.”
The TKI Era in Chronic Leukemias - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34959482/
1 Hematology and Transplant Center, University "Hospital San Giovanni di Dio e Ruggi D'Aragona", 84131 Salerno, Italy. 2 Unità Operativa di Trapianto di Cellule Staminali Ematopoietiche e Terapie Cellulari, Azienda...
Conclusion/Relevance: These tyrosine kinase inhibitors are well-tolerated, do have some associated in-class side effects that are manageable, and have remarkably improved outcomes for patients with hematologic malignancies.
-
Leukemia and Lymphoma Connect4yrKey Points • Source: Pharmaceutics • Conclusion/Relevance: “In conclusion, we highlight CML and CLL as examples of hematological malignancies in which the TKi-based approach was transformative and has remarkably improved outcomes for patients with Show More
The Conformational State of the BTK Substrate PLCγ Contributes to Ibrutinib Resistance - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34954235/
Mutations in PLCγ, a substrate of the tyrosine kinase BTK, are often found in patients who develop resistance to the BTK inhibitor Ibrutinib. However, the mechanisms by which these PLCγ...
Conclusion/Relevance: Improving our mechanistic understanding of how B cell signaling escapes Ibrutinib treatment via mutations in PLCγ will aid in the development of strategies to counter drug resistance.